Germany-based Bayer AG (ETR: BAYN) has announced that the Phase III OASIS 4 study for its non-hormonal treatment elinzanetant has reached all primary endpoints. The study focused on moderate to severe vasomotor symptoms (VMS) caused by adjuvant endocrine therapy in women with breast cancer or at high risk of developing breast cancer.
Study Results
The drug achieved statistically significant reductions in the frequency of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) from baseline to week 4 and 12 compared to placebo. The study also achieved all secondary endpoints, demonstrating reductions in the severity of VMS at week 4 and 12, VMS frequency reduction at week 1, and maintaining these effects over the study period.
Drug Profile
Elinzanetant is a dual neurokinin-1 and 3 (NK-1,3) receptor antagonist being developed to treat moderate to severe VMS associated with menopause or caused by adjuvant endocrine therapy for breast cancer. The treatment is administered orally once daily, offering a convenient and non-hormonal alternative for managing VMS.
Significance of the Study
The successful completion of the Phase III OASIS 4 study highlights the potential of elinzanetant as an effective treatment for vasomotor symptoms in women undergoing endocrine therapy for breast cancer. This development underscores Bayer’s commitment to advancing innovative therapies that improve the quality of life for patients.-Fineline Info & Tech
